Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several negative factors: a 3% decline in revenue, a decrease in gross margin, and a 10% drop in net income. Despite strategic initiatives and revenue growth expectations, the financial performance is weak, with increased R&D expenses and competitive pressures. Regulatory hurdles and market conditions pose additional risks. The lack of clarity in management responses during the Q&A further adds uncertainty. These factors suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue Revenue for Q1 2026 was $11.2 billion, a 3% decrease year-over-year, primarily due to lower sales of Revlimid as a result of generic competition.
Gross Margin Gross margin was 75%, down from 78% in Q1 2025, driven by an unfavorable product mix and increased manufacturing costs.
Research and Development (R&D) Expenses R&D expenses increased by 5% year-over-year to $2.3 billion, reflecting higher investments in clinical trials and pipeline development.
Net Income Net income for Q1 2026 was $1.8 billion, a 10% decrease compared to Q1 2025, attributed to lower revenue and higher operating expenses.
Earnings Per Share (EPS) EPS was $1.05, down 12% year-over-year, impacted by reduced net income and share repurchases.
Operating Expenses Operating expenses rose by 4% year-over-year to $4.5 billion, driven by increased R&D and marketing costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: Potential challenges in meeting regulatory requirements for new drug approvals, which could delay product launches and impact revenue.
Market Conditions: Unfavorable market conditions could affect the company's sales and profitability, particularly in key markets.
Competitive Pressures: Increased competition from other pharmaceutical companies could impact market share and pricing power.
Supply Chain Disruptions: Potential disruptions in the supply chain could affect the availability of raw materials and delay production schedules.
Economic Uncertainties: Economic instability in certain regions could impact the company's financial performance and strategic plans.
Strategic Execution Risks: Challenges in executing strategic initiatives could affect the company's growth and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The company is focusing on future product launches and market trends.
Revenue Expectations: The company expects revenue growth driven by new product launches and market expansion.
Margin Projections: Margins are expected to improve with operational efficiencies and cost management strategies.
Capital Expenditures: Planned capital expenditures will focus on expanding manufacturing capabilities.
Market Trends: The company anticipates a recovery in key markets and increased demand for innovative therapies.
Business Segment Performance: Growth is expected in the oncology and immunology segments, driven by new product approvals and market penetration.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Lenkowsky
Alexandria Hammond
Bank Research
Banking Markets
CFO Cristian
Chairman Elkins
Chen Scotiabank
Chief Commercialization
Commercialization Officer
Cristian Massacesi
Development Adam
Division Akash
Division Alexandria
Division EDT
Division Evan
Division Geoffrey
Division Louise
Division Mohit
Division Seamus
Division Terence
EDT Welcome
Evan Seigerman
Executive VP
Flynn Morgan
Global Banking
Hammond Wolfe
Head Investor
Investment Bank
LLC Research
LLC Schott
Louise Chen
Markets Research
Massacesi Executive
Securities LLC
VP Chief
BMY Transcript
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call highlights several negative factors: a 3% decline in revenue, a decrease in gross margin, and a 10% drop in net income. Despite strategic initiatives and revenue growth expectations, the financial performance is weak, with increased R&D expenses and competitive pressures. Regulatory hurdles and market conditions pose additional risks. The lack of clarity in management responses during the Q&A further adds uncertainty. These factors suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary highlights strong growth in key portfolios, increased revenue guidance, and a focus on transformative programs. The Q&A section reveals confidence in new drug potentials and strategic growth areas. Despite some management vagueness, the overall sentiment is bolstered by robust product performance and optimistic guidance, likely leading to a positive stock price reaction.
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
BMY Slides
BMY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
